Michael Hayden, MB, ChB, PhD, FRCP, FRSC, The University of British Columbia, Vancouver, Canada, & Prilenia, CEO, talks on huntingtin (HTT) post translational modifications (PTMs) and their pathophysiological relevance in the context of Huntington’s disease. HTT undergoes several PTMs in normal physiological conditions, including palmitoylation and phosphorylation, which are crucial in the regulation of its function. Notably, PTMs of HTT play a major role in its subcellular localization and regulation of interactions. Studies have showed reduced palmitoylation and phosphorylation in Huntington’s disease, leading to impaired trafficking and increased susceptibility to aggregation. Prof. Hayden highlights these modifications as a therapeutic opportunity. By normalizing HTT PTMs, it may be possible to improve normal function, stability, and clearance. Agents targeting these processes are currently under early investigation. This interview took place during the European Huntington’s Disease Network 2022 Plenary Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
